MEI Pharma Inc (MEIP) - Financial and Strategic SWOT Analysis Review

April 2021 | 43 pages | ID: MB03BF089847EN
GlobalData

Abstracts

MEI Pharma Inc (MEIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MEI Pharma Inc (MEI Pharma), formerly Marshall Edwards Inc, develops drugs for the treatment of cancer. The company’s drug candidates include pracinostat, an oral histone deacetylase inhibitor, intended for the treatment of advanced hematological diseases including myelodysplastic syndrome; ME-344, a mitochondrial inhibitor intended for the treatment of HER2-negative breast cancer and solid tumors; and Zandelisib (ME-401), an oral PI3K delta inhibitor for relapsed or refractory B-cell malignancies. The company also develops and commercializes Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor intented for the treatment of acute myeloid leukemia (AML) and B-cell malignancies through an agreement with Presage. MEI Pharma is headquartered in San Diego, California, the US.

MEI Pharma Inc Key Recent Developments

Apr 05,2021: MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference
Feb 04,2021: MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights
Nov 10,2020: MEI Pharma reports first quarter fiscal year 2021 results and operational highlights
Sep 09,2020: MEI Pharma reports fiscal year 2020 results and operational highlights
May 07,2020: MEI Pharma reports fiscal third-quarter 2020 results and recent corporate highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

MEI Pharma Inc - Key Facts
MEI Pharma Inc - Key Employees
MEI Pharma Inc - Key Employee Biographies
MEI Pharma Inc - Major Products and Services
MEI Pharma Inc - History
MEI Pharma Inc - Company Statement
MEI Pharma Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
MEI Pharma Inc - Business Description
R&D Overview
MEI Pharma Inc - Corporate Strategy
MEI Pharma Inc - SWOT Analysis
SWOT Analysis - Overview
MEI Pharma Inc - Strengths
MEI Pharma Inc - Weaknesses
MEI Pharma Inc - Opportunities
MEI Pharma Inc - Threats
MEI Pharma Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MEI Pharma Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 05, 2021: MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference
Feb 04, 2021: MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights
Nov 10, 2020: MEI Pharma reports first quarter fiscal year 2021 results and operational highlights
Sep 09, 2020: MEI Pharma reports fiscal year 2020 results and operational highlights
May 07, 2020: MEI Pharma reports fiscal third-quarter 2020 results and recent corporate highlights
Apr 14, 2020: MEI Pharma appoints Cheryl Cohen, product launch and commercialization veteran, to its board of directors
Feb 06, 2020: MEI Pharma reports fiscal second-quarter 2020 results and operational highlights

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

MEI Pharma Inc, Key Facts
MEI Pharma Inc, Key Employees
MEI Pharma Inc, Key Employee Biographies
MEI Pharma Inc, Major Products and Services
MEI Pharma Inc, History
MEI Pharma Inc, Key Competitors
MEI Pharma Inc, Ratios based on current share price
MEI Pharma Inc, Annual Ratios
MEI Pharma Inc, Annual Ratios (Cont...1)
MEI Pharma Inc, Interim Ratios
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MEI Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

MEI Pharma Inc, Performance Chart (2016 - 2020)
MEI Pharma Inc, Ratio Charts
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021